Rarity Bioscience raises €2,5M in seed funding to improve cancer care

Linus Bosaeus, CEO Rarity Bioscience

With the aim to improve cancer diagnostics, Rarity Bioscience has raised €2,5 million to expand operations and product development within precision diagnostics and liquid biopsy. The seed round was led by founders and joined by new investor, Navigare Ventures, owned by Wallenberg Investments AB. This investment round has come after a successful first year establishing […]

Free analysis for cancer researchers

Movember cancer

During November, Rarity Bioscience offer free analysis of liquid biopsy samples for cancer research. Movember is a month-long event to raise awareness of men’s health issues, and we want to do our part. Movember aims to increase early cancer detection, diagnosis, effective treatments and ultimately reduce the number of preventable deaths. At Rarity Bioscience, our vision […]

Podcast: Towards better health with Rarity

Speed of life podcast- Abe_Linus

Speed of Life is a podcast series focusing on innovations accelerating towards better health, by STUNS Life Science. It’s sponsored through a project funded by European Regional Development Fund (ERDF), Region Uppsala and STUNS Life Science. Rarity Bioscience, was invited to share our story. Our CTO and founder Lei Chen and Linus Bosaeus, CEO, were […]

One year: Research, innovation and improved patient outcome

Rarity Bioscience - året som gått

Rarity Bioscience was founded in July 2021 based on an innovation by Dr. Lei Chen and Professor Ulf Landegren. Linus Bosaeus was appointed as the CEO and shortly after, the seed round was raised. Since the start, the operational team has grown from two to eight employees and is still growing. Rarity celebrates one year […]

Best Poster Award 2022 at European Society for Medical Oncology

CEO Linus Bosaeus and co-founder and CTO Dr. Lei Chen attended the European Society for Medical Oncology Congress 2022, to learn more about the latest advancements in Liquid Biopsy and Minimal Residual Disease and make new contacts in the field. Dr. Lei Chen presented poster #629P; Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection […]

Rarity: Prestigious Skapa innovation Award winner 2022

We are delighted to share that Dr. Lei Chen has been awarded the prestigious Skapa innovation award, as winner of the region of Uppsala! Co-founder and CTO Lei Chen and co-nominee CEO Linus Bosaeus attended the award ceremony at the Uppsala Castle and received the award from Governor Göran Enander. The SKAPA Innovation Award is […]

superRCA published in Nature Communications

With an innovative, super sensitive technology, so-called superRCA, remaining cancer cells can be detected after treatment of acute myeloid leukemia (AML). The method is presented in an article in Nature Communication. The technology, superRCA, tracks mutations with greater sensitivity than PCR-based technologies and can detect recurrence of cancer earlier. The technology is fast, sensitive, reliable […]

Raritys teknik är 10 till 100 gånger mer känslig än dagens teknik

Inte ens ett år gamla har Rarity Bioscience fått anslag från Swelife och Medtech4health. Nu hoppas Linus Bosaeus, vd på Rarity, att tekniken för detektion av mutationer i blodprov hos cancerpatienter ska nå laboratorier redan nästa år. “Vår teknik är 10 till 100 gånger mer känslig än dagens teknik och kan upptäcka en mutation på […]

Rarity support Elicera Therapeutics in cutting edge CAR-T therapy study

car-t white paper

On behalf of the sponsor, Elicera Therapeutics, Rarity is supporting the ELC301 translational study with analysis of the vector copy number (VCN) of integrated retroviral vectors in engineered Human T-cells. “The assay from Rarity shows similar or better CV than current available ddPCR assays, and a much more cost efficient alternative. Based on the sensitivity […]

Poster presented at EACR Liquid Biopsy

Poster presentation by Lei Chen,PhD at the European Association for Cancer Research conference on Liquid Biopsy in Bergamo, Italy. The poster focused on the superRCA single tube assay workflow, the assay sensitivity and precision, followed by multiplex example from colorectal patients. “Great conference and lots of attention and positive response, also amazing to see so […]